financetom
Business
financetom
/
Business
/
GlobalFoundries forecasts weak Q1 amid tariff concerns and smartphone sector struggles
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GlobalFoundries forecasts weak Q1 amid tariff concerns and smartphone sector struggles
Feb 11, 2025 5:59 AM

Feb 11 (Reuters) -

GlobalFoundries ( GFS ) on Tuesday forecast first-quarter

revenue and profit below Wall Street estimates as the contract

chipmaker braces for the potential impact of President Donald

Trump's tariffs on automaker clients and a challenging

smartphone market in 2025.

Shares of the Malta, New York State-based company were down

5.1% before the bell.

GlobalFoundries ( GFS ) expects its first quarter revenue between

$1.55 billion and $1.60 billion. Analysts were expecting $1.66

billion, according to data compiled by LSEG.

The automotive sector, the company's third-largest revenue

segment, is particularly vulnerable to the effects of tariffs on

steel and aluminum imports in the U.S.

GlobalFoundries ( GFS ) signed a

long-term agreement

with General Motors ( GM ) in 2023 to establish dedicated

production capacity exclusively for the Detroit-based carmaker

at the chipmaker's Malta facility.

The company's biggest segment, smartphones, is also under

pressure, with the global smartphone market expected to be

turbulent in 2025, according to research firm Canalys.

On an adjusted basis, GlobalFoundries ( GFS ) expects to earn

between 24 cents per share and 34 cents per share in the first

quarter, the mid-point of which is below analyst estimates of 32

cents.

The world's third-largest chipmaker posted revenue of $1.83

billion in the fourth quarter, which missed analysts' estimates

of $1.98 billion, according to data compiled by LSEG.

Excluding items, GlobalFoundries ( GFS ) posted a profit of 46 cents

per share in the fourth quarter, compared to analysts'

expectations of 57 cents per share.

Earlier this month, the chipmaker appointed Tim Breen as its

CEO, succeeding Thomas Caulfield.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biogen Partner Eisai Submits FDA Biologics Application for Early Alzheimer's Self-Injection Drug
Biogen Partner Eisai Submits FDA Biologics Application for Early Alzheimer's Self-Injection Drug
May 15, 2024
04:26 AM EDT, 05/15/2024 (MT Newswires) -- Biogen (BIIB) and Eisai said Tuesday that the latter has initiated a rolling submission of a biologics license application to the US Food and Drug Administration for lecanemab-irmb subcutaneous autoinjector as a weekly maintenance treatment for early Alzheimer's disease. The application came after the treatment, commercially known as Leqembi, was granted FDA fast-track...
New York Community Bancorp to Sell $5 Billion in Mortgage Warehouse Loans to JPMorgan Chase Bank
New York Community Bancorp to Sell $5 Billion in Mortgage Warehouse Loans to JPMorgan Chase Bank
May 15, 2024
04:12 AM EDT, 05/15/2024 (MT Newswires) -- New York Community Bancorp ( NYCB/PU ) said Tuesday it has entered into a commitment letter to sell about $5 billion in mortgage warehouse loans to JPMorgan Chase Bank. The sale is expected to close in Q3. Shares of New York Community Bancorp gained almost 6% in after-market hours on Tuesday. Price: 4.1200,...
Novonix Signs Testing, Development Deal With Volkswagen-Owned PowerCo
Novonix Signs Testing, Development Deal With Volkswagen-Owned PowerCo
May 15, 2024
04:32 AM EDT, 05/15/2024 (MT Newswires) -- Novonix ( NVX ) said late Tuesday it signed a non-exclusive testing and development agreement with Volkswagen-owned PowerCo to come up with synthetic graphite anode materials for electric vehicle batteries. The companies could later enter into a supply agreement for the products developed under the deal, Novonix ( NVX ) said. Financial terms...
Update: Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket
Update: Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket
May 15, 2024
04:24 AM EDT, 05/15/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.) Arcutis Biotherapeutics' ( ARQT ) shares surged more than 20% in premarket activity on Wednesday after the company reported a narrower loss and handily beat market expectations for sales. The company reported a Q1 loss late Tuesday of $0.32 per diluted...
Copyright 2023-2026 - www.financetom.com All Rights Reserved